Veerhealth Care (511523)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 89.06% shows strong topline momentum
• Profit growth of 471.43% indicates potential operational leverage
• Piotroski F-Score of 7/9 suggests improving financial health
• Low or negligible debt (Debt/Equity N/A) reduces balance sheet risk
• PEG ratio of 0.18 implies growth is not fully priced if sustained

Concerns

• Latest quarter shows ₹7 Cr sales but ₹0 Cr net profit — earnings fragility
• ROE of 3.59% and ROCE of 3.14% are far below acceptable returns on capital
• P/E of 49.87 with no dividend yield leaves no income cushion
• Promoter holding not disclosed, reducing governance transparency

AI Analysis

When I look at Veerhealth Care, I see a classic small-cap pharma story with headline numbers that demand careful scrutiny. Sales grew 89% and profits rose 471% — those are eye-catching figures. But as Graham taught, a thousand plants can grow in a single summer; the real question is whether they survive the winter. The latest quarter tells a sobering tale: sales of just ₹7 crore and net profit of ₹0 crore. That suggests the celebrated profit growth may be from a low base or non-recurring factors. Return on equity is only 3.59%, and ROCE is 3.14% — barely above what a bank fixed deposit would earn. At a P/E of 49.87, the market is paying a premium for growth that hasn't yet translated into durable earnings. Book value is ₹11.01, so the P/B of 2.17 isn't outrageous, but with zero dividend yield, shareholders rely entirely on capital appreciation. I note the Piotroski F-Score of 7/9, which hints at improving fundamentals, but one strong year does not create a moat. In pharmaceuticals, we need patent protection, brand strength, or distribution advantages — none are evident from these numbers. Debt/equity is not disclosed, but the apparent lack of leverage could be a positive. Ultimately, this looks like a fast grower in its early stage, but I would wait for consistent profitability before committing capital. With the price near its 52-week high of ₹24.00, there is little margin of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer